Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trialBirgit Geoerger, Navin Pinto, Hyoung Jin Kang et al.|The Lancet Oncology|2019Cited by 341
Mobilization of hobo elements residing within the decapentaplegic gene complex: Suggestion of a new hybrid dysgenesis system in Drosophila melanogasterRonald K. Blackman, William M Gelbart, R Grimaila et al.|Cell|1987Cited by 190
Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)Ami V. Desai, Elizabeth Fox, Giles Robinson et al.|Neuro-Oncology|2022Cited by 136
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C. Goldsmith, Yaël P. Mossé, Yueh‐Yun Chi et al.|Nature Medicine|2023Cited by 125
CFEOM3: a new extraocular congenital fibrosis syndrome that maps to 16q24.2-q24.3.E J Doherty, Elizabeth C. Engle, Margaret E. Macy et al.|PubMed|1999Cited by 104